Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring.
Androgen blockade
Apoptosis
Enzalutamide
Prostate cancer
Radiotherapy
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
18
09
2018
revised:
12
12
2018
accepted:
07
02
2019
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
ppublish
Résumé
To evaluate the radiopotentiation of enzalutamide in human prostate cancer cells. While radiotherapy is the first line of treatment for prostate cancer, androgen blockade therapies are demonstrating significant survival benefit as monotherapies. As androgen blockade can cause cell death by apoptosis, it is likely that androgen blockade will potentiate the cytotoxic activities of radiotherapy. Here, we tested the potential synergistic effects of these two treatments over two human metastatic prostate cancer cells by real-time cell analysis (RTCA), androgen-sensitive LNCaP cells (Lymph Node Carcinoma of the Prostate) and androgen-independent PC-3. Both cell lines were highly resistant to high doses of radiotherapy. A pre-treatment of LNCaP cells with IC50 concentrations of enzalutamide significantly sensitized them to radiotherapy through enhanced apoptosis. In contrast, enzalutamide resistant PC-3 cells were not sensitized to radiotherapy by androgen blockade. These results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.
Sections du résumé
AIM
OBJECTIVE
To evaluate the radiopotentiation of enzalutamide in human prostate cancer cells.
BACKGROUND
BACKGROUND
While radiotherapy is the first line of treatment for prostate cancer, androgen blockade therapies are demonstrating significant survival benefit as monotherapies. As androgen blockade can cause cell death by apoptosis, it is likely that androgen blockade will potentiate the cytotoxic activities of radiotherapy.
MATERIALS AND METHODS
METHODS
Here, we tested the potential synergistic effects of these two treatments over two human metastatic prostate cancer cells by real-time cell analysis (RTCA), androgen-sensitive LNCaP cells (Lymph Node Carcinoma of the Prostate) and androgen-independent PC-3. Both cell lines were highly resistant to high doses of radiotherapy.
RESULTS
RESULTS
A pre-treatment of LNCaP cells with IC50 concentrations of enzalutamide significantly sensitized them to radiotherapy through enhanced apoptosis. In contrast, enzalutamide resistant PC-3 cells were not sensitized to radiotherapy by androgen blockade.
CONCLUSIONS
CONCLUSIONS
These results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.
Identifiants
pubmed: 30858765
doi: 10.1016/j.rpor.2019.02.002
pii: S1507-1367(19)30017-3
pmc: PMC6395847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
221-226Références
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
J Med Chem. 2010 Apr 8;53(7):2779-96
pubmed: 20218717
Lancet. 2010 Apr 24;375(9724):1437-46
pubmed: 20398925
PLoS One. 2012;7(10):e46536
pubmed: 23094027
Cancer J. 2013 Jan-Feb;19(1):43-9
pubmed: 23337756
J Natl Cancer Inst. 2013 May 15;105(10):711-8
pubmed: 23615689
J Med Chem. 2013 Jun 27;56(12):4880-98
pubmed: 23713567
Clin Med Insights Oncol. 2013 Aug 21;7:235-45
pubmed: 24179414
Clin Cancer Res. 2014 Jun 15;20(12):3198-3210
pubmed: 24740322
N Engl J Med. 2014 Oct 30;371(18):1755-6
pubmed: 25354111
Biosensors (Basel). 2015 Apr 16;5(2):199-222
pubmed: 25893878
Oncotarget. 2015 Sep 29;6(29):27160-75
pubmed: 26320174
Oncotarget. 2016 Jun 28;7(26):40690-40703
pubmed: 27276681
Mol Cancer Ther. 2017 Jul;16(7):1389-1400
pubmed: 28468774
Prostate. 2018 Jan;78(1):64-75
pubmed: 29134684